Movement Alert|GENSCRIPT B-1K Intraday Rise 8.88% in Regular Trading, AIDD Growth Outlook and Profit Forecast Upgrade Lift Sentiment

Market Focus11-10

On November 10, GENSCRIPT B-1K rose 8.88% in regular trading, trading at HK$34.68, with turnover of HK$217 million.

The move was tied to a fresh broker view after the company’s recent investor day, where management discussed AIDD opportunities, platform buildout, business positioning, and long-term growth strategy. The update said the addressable market for life science AIDD could grow at a 50% to 80% compound rate over the next three years, with AIDD expected to drive wet-lab orders through new customer additions, faster iteration cycles, higher validation throughput, and deeper experimental demand.

Recent sector strength also provided support, with peers including WUXI APPTEC, WUXI BIO, XTALPI, and INSILICO moving higher, reinforcing the market’s focus on AI-enabled drug discovery and outsourced life sciences services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment